Temporal evolution of C-reactive protein levels and its association with the incident hospitalization risk among individuals with stage 3–4 chronic kidney disease
Tóm tắt
Elevated C-reactive protein (CRP) levels as an inflammatory marker have been associated with poor outcomes in patients with chronic kidney disease (CKD). However, its single assessment may not reflect clinical significance before an adverse clinical endpoint. We studied the CRP level trajectories, which may be related with the intensity of the inflammatory process, and its association with time-to-first hospitalization in CKD. A cohort of 739 patients with stage 3–4 CKD were retrospectively observed for seven years. The time-to-event outcome was all-cause hospitalization. Clinical and laboratory features were measured at baseline. Longitudinal changes in naturally logged CRP levels were modeled using the Joint Longitudinal-Survival model adjusted with baseline covariates. Logged CRP changes were evaluated with a median measurement (interquartile range) of 4 (2, 7), during a median (interquartile range) follow-up of 2.3 (1.2, 3.9) years. The estimated mean increase in logged CRP was 0.35 mg/L per year. 299 (40.5%) patients reached the endpoint, and increase in logged CRP with time was associated with increased risk of hospitalization (HR 1.96; 95% CI 1.05–3.66; p = 0.034), but baseline logged CRP did not have a significant effect on the time-to-first hospitalization (HR 0.98; 95% CI 0.85–1.13; p = 0.736). All-cause hospitalization was associated significantly with CRP trajectories. Temporal evolutions of these repeatedly measured biomarkers might predict clinical outcomes in patients with CKD and may be useful for individual risk profiling. Furthermore, early management may provide an opportunity to better patient survival.
Tài liệu tham khảo
Nitsch D, Nonyane BAS, Smeeth L et al (2011) CKD and hospitalization in the elderly: a community-based cohort study in the United Kingdom. Am J Kidney Dis 57:664–672. https://doi.org/10.1053/j.ajkd.2010.09.026
Mix T-CH, St-peter WL, Ebben J et al (2003) Hospitalization during advancing chronic kidney disease. Am J Kidney Dis 42:972–981. https://doi.org/10.1016/j.ajkd.2003.06.001
Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305. https://doi.org/10.1056/NEJMoa041031
Kent S, Schlackow I, Lozano-Kühne J et al (2015) What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrol 16:65. https://doi.org/10.1186/s12882-015-0054-0
Levey AS, de Jong PE, Coresh J et al (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80:17–28. https://doi.org/10.1038/ki.2010.483
Saran R, Robinson B, Abbott KC, Agodoa LY, Bhave N, Bragg-Gresham J (2018) US renal data system 2017 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 71:A7
Diamond JR (1991) Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 31:S29-34
Schmidt MI, Duncan BB, Sharrett AR et al (1999) Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet 353:1649–1652. https://doi.org/10.1016/s0140-6736(99)01046-6
Shankar A, Sun L, Klein BEK et al (2011) Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int 80:1231–1238. https://doi.org/10.1038/ki.2011.283
Kendrick J, Chonchol MB (2008) Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 4:672–681. https://doi.org/10.1038/ncpneph0954
Shlipak MG, Fried LF, Crump C et al (2003) Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107:87–92. https://doi.org/10.1161/01.cir.0000042700.48769.59
Tonelli M, Sacks F, Pfeffer M et al (2005) Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68:237–245. https://doi.org/10.1111/j.1523-1755.2005.00398.x
Fried L, Solomon C, Shlipak M et al (2004) Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 15:3184–3191. https://doi.org/10.1097/01.ASN.0000146422.45434.35
Wang Z, Hoy WE (2010) C-reactive protein: an independent predictor of cardiovascular disease in aboriginal Australians. Aust NZJ Public Health 34(Suppl 1):S25–S29. https://doi.org/10.1111/j.1753-6405.2010.00548.x
Arnold LW, Hoy WE, Wang Z (2017) The association between C-reactive protein levels and the risk for chronic kidney disease hospitalizations in adults of a remote Indigenous Australian community—a prospective cohort study. Nephrology (Carlton) 22:699–705. https://doi.org/10.1111/nep.12841
Chesnaye NC, Tripepi G, Dekker FW et al (2020) An introduction to joint models-applications in nephrology. Clin Kidney J 13:143–149. https://doi.org/10.1093/ckj/sfaa024
Anderson AH, Yang W, Hsu C et al (2012) Estimating GFR among participants in the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis 60:250–261. https://doi.org/10.1053/j.ajkd.2012.04.012
Zhang X, Bansal N, Go AS et al (2015) Gastrointestinal symptoms, inflammation and hypoalbuminemia in chronic kidney disease patients: a cross-sectional study. BMC Nephrol 16:211. https://doi.org/10.1186/s12882-015-0209-z
Myers GL, Rifai N, Tracy RP et al (2004) CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the laboratory science discussion group. Circulation 110:e545–e549. https://doi.org/10.1161/01.CIR.0000148980.87579.5E
Chonchol M, Gnahn H, Sander D (2008) Impact of subclinical carotid atherosclerosis on incident chronic kidney disease in the elderly. Nephrol Dial Transplant 23:2593–2598. https://doi.org/10.1093/ndt/gfn021
Crowther MJ, Abrams KR, Lambert PC (2013) Joint modeling of longitudinal and survival data. Stand Genomic Sci 13:165–184. https://doi.org/10.1177/1536867X1301300112
Sun GW, Shook TL, Kay GL (1996) Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 49:907–916. https://doi.org/10.1016/0895-4356(96)00025-x
Crowther MJ (2013) STJM: stata module to fit shared parameter joint models of longitudinal and survival data. Department of Economics, Boston College, Boston
Barnett AG, van der Pols JC, Dobson AJ (2005) Regression to the mean: what it is and how to deal with it. Int J Epidemiol 34:215–220. https://doi.org/10.1093/ije/dyh299
Vigushin DM, Pepys MB, Hawkins PN (1993) Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 91:1351–1357. https://doi.org/10.1172/JCI116336
Fox ER, Benjamin EJ, Sarpong DF et al (2010) The relation of C–reactive protein to chronic kidney disease in African Americans: the jackson heart study. BMC Nephrol 11:1. https://doi.org/10.1186/1471-2369-11-1
Stuveling EM, Hillege HL, Bakker SJL et al (2003) C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 63:654–661. https://doi.org/10.1046/j.1523-1755.2003.00762.x
Xia H, Ebben J, Ma JZ et al (1999) Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309–1316
Dalrymple LS, Mu Y, Nguyen DV et al (2015) Risk factors for infection-related hospitalization in in-center hemodialysis. Clin J Am Soc Nephrol 10:2170–2180. https://doi.org/10.2215/CJN.03050315